. Author manuscript; available in PMC: 2020 Nov 24.

Published in final edited form as: Curr Opin Virol. 2020 Oct 23;43:79–87. doi: 10.1016/j.coviro.2020.09.005

Table 3:

Tetravalent admixtures evaluated in clinical trial

	Administered dose of each component (log₁₀ PFU)	Monovalent dengue vaccine component
	Administered dose of each component (log₁₀ PFU)	DENV-1	DENV-2	DENV-3	DENV-4
TV001	3,3,3,3	rDEN1Δ30	rDEN2/4Δ30	rDEN3–3’D4Δ30	rDEN4Δ30
TV002	3,3,3,3	rDEN1Δ30	rDEN2/4Δ30	rDEN3–3’D4Δ30	rDEN4Δ30–200,201
TV003	3,3,3,3	rDEN1Δ30	rDEN2/4Δ30	rDEN3Δ30,31	rDEN4Δ30
TV004	3,3,3,3	rDEN1Δ30	rDEN2/4Δ30	rDEN3Δ30,31	rDEN4Δ30–200,201
TV005	3,4,3,3	rDEN1Δ30	rDEN2/4Δ30	rDEN3Δ30,31	rDEN4Δ30

^1.

Bolded formulations are those chosen to move forward for further evaluation